A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2018
At a glance
- Drugs APG-2575 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 13 Aug 2018 Status changed from not yet recruiting to recruiting.
- 24 Jul 2018 Planned initiation date changed from 28 Jun 2018 to 7 Aug 2018.
- 29 May 2018 New trial record